Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.
about
Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug ResistanceCell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirinRibavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.The proteome of sickle cell disease: insights from exploratory proteomic profiling.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionAntiviral activity and possible mechanism of action of constituents identified in Paeonia lactiflora root toward human rhinoviruses.Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy.Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.Role of ribavirin in HCV treatment response: now and in the future.Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro.Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse.Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats.Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats.HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes.Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.Inhibition of warfarin activity by ribavirin.Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites.Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.Antioxidant and Membrane Binding Properties of Serotonin Protect Lipids from Oxidation.
P2860
Q24530833-E7BA99B6-8BD0-4403-BF75-A806C3404185Q24594939-46D3D0B8-322E-4548-8B35-24667C8B3EFEQ27488307-124B04B0-0FEE-4CF3-B248-5CFD2C8F4874Q28474617-9AE5819C-7E56-49D7-9235-B6FC83488E0BQ33782525-6246B2E3-A541-437C-981F-069AB299945AQ33815550-5BA3A8A3-F832-4989-86CB-9E192BA7FF8AQ34746400-B211A80A-C9B0-47D5-83F9-A50107B2151FQ35066350-CAEB06AD-413F-4484-9729-E62AEC04C170Q35073553-EAD049CC-7FAC-44C4-BE4B-26078E99BBCBQ35077712-F73D8E77-3D10-40C8-B180-948546C9CCB0Q35169059-0BAE6650-1B83-4DD3-901C-55762BECF828Q35362286-943DFD9C-6096-47C6-8BC8-DD605F00E1D7Q35802787-83B13343-D14C-4862-82BF-D75346ED8C7CQ36146443-4B79BD2A-75F8-4478-A104-B12EE319D35FQ36205383-22D5C4C6-0EEE-4F00-89E1-C2E566B94E9CQ36236463-69F4465A-36B5-41CC-8F7E-4B27C1F49C81Q36877307-0565B1DE-B51C-4938-BB42-45707B3FD846Q37162156-47F0B59D-26A1-47D8-B956-78D2A80B9FF9Q37397265-582FCF02-187A-48D3-B775-FE6EFA537BDEQ37693948-4D4FF5CC-DE13-44F0-B8D7-EDD1959F9C4FQ37834510-CB9A8444-35E3-41F8-B527-2543D4552143Q38203823-CADE0403-7FD5-4971-888E-0D87E964F8FBQ38707179-25DC56A7-57C9-4695-B240-1762603AD328Q38990833-D354DA45-BE14-45BB-9FE8-6EFBEBCCF406Q39434360-9E6781DA-7982-4247-832C-922452B5EE32Q39472205-65402E8B-452E-4EB2-8EEF-45CF56AD3F0FQ39869989-C473D28C-0C62-4FC3-9979-77E10873CC40Q40164303-27435B08-D820-4200-B8DE-7E988310C6B6Q40668772-86FA0A09-BE09-41B2-9E2C-953F2699BF86Q40755393-B859DBA6-0055-4B37-A9C5-6DC3FAC879F9Q40816050-45AF4344-0636-4341-AE26-8FB4562A5EC9Q40821539-001E9273-C690-4BB1-8A32-F5AB00B632B9Q40931542-EACA7629-C1FF-43C6-8BEF-D6EEDFC8AE50Q42839633-15EF987C-8B03-43F8-91B8-74E9D45C5E58Q43030470-E687DB4D-A5BA-4AAB-97B7-43AFA5860AD2Q43047106-3046EC0C-03EF-4C63-9492-CEC94DEDDC06Q43869933-6745A1BB-A044-4C90-A4DE-8DF720722E74Q43988787-279EED96-3DDE-4B07-A527-1DB5763EF710Q44115945-4F2302C1-0AD0-4F65-8B94-00A1A970677EQ46367472-56BF6B9C-0344-4E93-AE9D-D8782ED253CD
P2860
Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@ast
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@en
type
label
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@ast
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@en
prefLabel
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@ast
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@en
P2860
P356
P1476
Ribavirin uptake by human eryt ...... (es)-nucleoside transporters.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0701775
P407
P50
P577
1998-04-01T00:00:00Z